Valentina Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina Martin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Agustina Palumbo
Centro de Estudios en Salud y Medio Ambiente, ITECA, ECyT, UNSAM, CONICET, Buenos Aires, Argentina
2 shared publicationsAlejandra Goldman
Centro de Estudios en Salud y Medio Ambiente, ITECA, ECyT, UNSAM, CONICET, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Buenos Aires, Argentina
2 shared publicationsIgnacio M. Fenoy
Centro de Estudios en Salud y Medio Ambiente, ITECA, ECyT, UNSAM, CONICET, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Buenos Aires, Argentina
2 shared publicationsNadia Arcon
Centro de Estudios en Salud y Medio Ambiente, ITECA, ECyT, UNSAM, CONICET, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Buenos Aires, Argentina
2 shared publications- Vanesa R. Sanchez
Centro de Estudios en Salud y Medio Ambiente, ITECA, ECyT, UNSAM, CONICET, Buenos Aires, Argentina
2 shared publications Victoria Pastor
Centro de Estudios en Salud y Medio Ambiente, ITECA, ECyT, UNSAM, CONICET, Buenos Aires, Argentina
2 shared publications
Latest Publications
- 23 June 2026
- Published by Elsevier in Acta Tropica
- Vol. 280, 108197
The immune-stimulating particle adjuvant (ISPA) as a versatile adjuvant platform for recombinant vaccines against chronic Toxoplasma gondii infection
- 23 June 2026
- Published by Elsevier in Acta Tropica
- Vol. 280, 108197
The immune-stimulating particle adjuvant (ISPA) as a versatile adjuvant platform for recombinant vaccines against chronic Toxoplasma gondii infection
- Open Access
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
The Immune-Stimulating Particle Adjuvant (ISPA) as a Versatile Adjuvant Platform for Recombinant Vaccines Against Chronic Toxoplasma gondii Infection
Toxoplasma gondii is a widespread intracellular parasite that establishes chronic infection through the persistence of tissue cysts, for which no effective treatment or licensed vaccines for humans are currently available. Preventive vaccination of animal hosts represents a promising strategy to reduce parasite transmission and disease burden. In this study, we evaluated the immunogenicity and protective efficacy of recombinant subunit vaccines based on T. gondii GRA7, ROP2, or profilin (TgPF) formulated with the Immune-Stimulating Particle Adjuvant (ISPA), a saponin-based particulate adjuvant structurally related to ISCOMATRIX. C57BL/6 mice were immunized intradermally and orally challenged with a sublethal dose of T. gondii ME49 cysts. Vaccines formulated with ISPA induced robust antigen-specific immune responses, characterized by increased IgG levels with a mixed IgG1/IgG2b profile, enhanced splenocyte proliferation, and the activation of IFN-γ–producing CD4⁺ and CD8⁺ T cells accompanied by regulated IL-10 production. Importantly, all ISPA-adjuvanted formulations significantly reduced brain cyst burden compared with control groups, whereas recombinant proteins or ISPA administered alone failed to confer protection. These results provide the first evidence supporting the use of ISPA as an adjuvant in T. gondii subunit vaccines and highlight its potential as a safe and effective platform for inducing balanced humoral and cellular immunity against intracellular pathogens.
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Immune-Stimulating Particle Adjuvant (ISPA) as a Versatile Adjuvant Platform for Recombinant Vaccines Against Chronic Toxoplasma gondii Infection
Toxoplasma gondii is a widespread intracellular parasite that establishes chronic infection through the persistence of tissue cysts, for which no effective treatment or licensed vaccines for humans are currently available. Preventive vaccination of animal hosts represents a promising strategy to reduce parasite transmission and disease burden. In this study, we evaluated the immunogenicity and protective efficacy of recombinant subunit vaccines based on T. gondii GRA7, ROP2, or profilin (TgPF) formulated with the Immune-Stimulating Particle Adjuvant (ISPA), a saponin-based particulate adjuvant structurally related to ISCOMATRIX. C57BL/6 mice were immunized intradermally and orally challenged with a sublethal dose of T. gondii ME49 cysts. Vaccines formulated with ISPA induced robust antigen-specific immune responses, characterized by increased IgG levels with a mixed IgG1/IgG2b profile, enhanced splenocyte proliferation, and the activation of IFN-γ–producing CD4⁺ and CD8⁺ T cells accompanied by regulated IL-10 production. Importantly, all ISPA-adjuvanted formulations significantly reduced brain cyst burden compared with control groups, whereas recombinant proteins or ISPA administered alone failed to confer protection. These results provide the first evidence supporting the use of ISPA as an adjuvant in T. gondii subunit vaccines and highlight its potential as a safe and effective platform for inducing balanced humoral and cellular immunity against intracellular pathogens.